866-997-4948(US-Canada Toll Free)

Global Alzheimers Drugs Market 2017-2021

Published By :

Technavio

Published Date : Jul 2017

Category :

Therapeutic Area

No. of Pages : 102 Pages

About Alzheimer's Drugs

Alzheimer's disease is a progressive and irreversible degeneration of the brain that disrupts the thinking, language, behavior, and cognitive skills of a person. It is more prevalent in people aged 65 years and above and affects more women than men. As per the Centers for Disease Control and Prevention (CDC), 5.4 million Americans are affected by this disease, and the incidence rate of disease increases with age and doubles every five years for adults beyond 65 years of age.

Technavios analysts forecast the global alzheimer's drugs market to grow at a CAGR of 1.90% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global alzheimer's drugs market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Alzheimer's Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
ALLERGAN
Eisai Pharmaceuticals
Johnson & Johnson
Novartis

Other prominent vendors
Amgen
Pfizer

Market driver
Appropriate strategies designed to increase public awareness
For a full, detailed list, view our report

Market challenge
Social stigma associated with Alzheimer's disease
For a full, detailed list, view our report

Market trend
Reformulation of marketed drugs
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.




PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
Market outline
PART 05: Alzheimer's disease: An overview
National Alzheimer's Project
PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by MoA
AChE inhibitors
Glutamate inhibitors
PART 09: Market assessment of FDA-approved drugs
Aricept
Exelon
NAMENDA
Razadyne
PART 10: Geographical segmentation
Alzheimer's drugs market in Americas
Alzheimer's drugs market in EMEA
Alzheimer's drugs market in APAC
PART 11: Decision framework
PART 12: Drivers and challenges
Market drivers
Market challenges
PART 13: Market trends
Rising government initiatives to support Alzheimer's disease
Rising burden of Alzheimer's disease
Reformulation of marketed drugs
PART 14: Vendor landscape
Competitive scenario
PART 15: Key vendor analysis
ALLERGAN
Eisai Pharmaceuticals
Johnson & Johnson
Novartis
Other prominent vendors
PART 16: Appendix
List of abbreviations

List of Exhibits
Exhibit 01: Alzheimer disease: A brief overview
Exhibit 02: Progression of Alzheimer's disease
Exhibit 03: Mechanism of pathogenesis of Alzheimer's disease
Exhibit 04: Risk factors responsible for development of Alzheimer's disease
Exhibit 05: Alzheimer's disease treatment: Milestones
Exhibit 06: Vendor's initiative for promoting Alzheimer's drugs business
Exhibit 07: Global Alzheimer's drugs market: Snapshot
Exhibit 08: Global Alzheimer's drugs market 2016-2021 ($ millions)
Exhibit 09: Opportunity analysis of global Alzheimer's drugs market
Exhibit 10: Five forces analysis
Exhibit 11: Pipeline snapshot based on number of molecules
Exhibit 12: Key clinical trials
Exhibit 13: Alzheimer's drugs with fast track designation
Exhibit 14: Market segmentation based on MoA
Exhibit 15: Global Alzheimer's drugs market share based on MoA
Exhibit 16: Global Alzheimer's AChE inhibitors drugs market 2016-2021 ($ millions)
Exhibit 17: Global Alzheimer's glutamate inhibitors drugs market 2016-2021 ($ millions)
Exhibit 18: FDA-approved drugs for the treatment of Alzheimer's disease
Exhibit 19: Key events timeline for Aricept formulations in Japan
Exhibit 20: Key events timeline for Aricept in US and Europe
Exhibit 21: Exelon revenue 2015 and 2016 ($ millions)
Exhibit 22: Key events timeline for Exelon formulation
Exhibit 23: NAMENDA revenue 2015 and 2016 ($ millions)
Exhibit 24: Key events timeline for NAMENDA
Exhibit 25: Razadyne revenue 2015 and 2016 ($ millions)
Exhibit 26: Key events timeline for Razadyne
Exhibit 27: Global Alzheimer's drugs market share by geography 2016 and 2021
Exhibit 28: Global Alzheimer's drugs market revenue by geography 2016-2021
Exhibit 29: Alzheimer's drugs market scenario in different geographies
Exhibit 30: Market scenario in Americas
Exhibit 31: Alzheimer's drugs market in Americas 2016-2021 ($ millions)
Exhibit 32: Market scenario in EMEA
Exhibit 33: Alzheimer's drugs market in EMEA 2016-2021 ($ millions)
Exhibit 34: Market scenario in APAC
Exhibit 35: Alzheimer's drugs market revenue in APAC 2016-2021 ($ millions)
Exhibit 36: Death rate per 100,000 of US population due to Alzheimer's disease 2010-2014
Exhibit 37: Revenue erosion of Aricept after loss of exclusivity
Exhibit 38: Estimated number of people aged 65 and older with Alzheimer's disease in the US, 2010-2050
Exhibit 39: Competitive structure analysis of global Alzheimer's drugs market 2016
Exhibit 40: ALLERGAN: Key highlights
Exhibit 41: ALLERGAN: Strength assessment
Exhibit 42: ALLERGAN: Strategy assessment
Exhibit 43: ALLERGAN: Opportunity assessment
Exhibit 44: Eisai Pharmaceuticals: key highlights
Exhibit 45: Eisai Pharmaceuticals: Strength assessment
Exhibit 46: Eisai Pharmaceuticals: Strategy assessment
Exhibit 47: Eisai Pharmaceuticals: Opportunity assessment
Exhibit 48: Johnson & Johnson: Key highlights
Exhibit 49: Johnson & Johnson: Strength assessment
Exhibit 50: Johnson & Johnson: Strategy assessment
Exhibit 51: Johnson & Johnson: Opportunity assessment
Exhibit 52: Novartis: Key highlights
Exhibit 53: Novartis: Strength assessment
Exhibit 54: Novartis: Strategy assessment
Exhibit 55: Novartis: Opportunity assessment

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *